NCT05997342 - A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 16, 2023

Primary Completion Date

May 27, 2025

Study Completion Date

May 27, 2025

Conditions

Advanced Malignant Neoplasm

Interventions

DRUG

TQB3912 tablets

TQB3912 is a small molecule Phosphorylated protein kinase inhibitor. Activation of the pathway plays an important role in cell survival, proliferation, migration, and differentiation.

Trial Locations (2)

410013

Hunan Cancer Hospital, Changsha

610000

West China hospital, Sichuan university, Chengdu